Purpose:To determine whether bromfenac as a single agent is just as safe and effective as a corticosteroid in post-operative cataract surgery.Methods:Retrospective chart review compared over 400 eyes undergoing cataract surgery. Two hundred eyes were analyzed in each group. The first group received topical Pred Forte® 1 % (prednisolone acetate 1 %, Allergan) four times daily for two weeks, then tapered over the following three weeks, and the second group had topical Bromday™ (bromfenac 0.09 %, ISTA) as a single agent once daily, two days before surgery and for four weeks after. Outcomes measured were best corrected visual acuity (BCVA), post-operative pain, inflammation, cystoid macular edema (CME), and raised intraocular pressure (IOP).Results:Both groups had excellent vision improvement, to 20/27.2 (Pred Forte group) and 20/26.6 (Bromday group) average BCVA at one month post-operation. Both groups had excellent pain and inflammatory control at the one-day, two-week, and one-month time points. There were two eyes (1 %) in the steroid group with CME and only one eye (0.5 %) in the Bromday group. Most remarkably, when looking at one week post-operation or later, there were 16 eyes (8 %) in the corticosteroid group with an elevation in IOP greater than 5 mmHg above baseline, and only five eyes (2.5 %) in the Bromday group (p=0.02) had IOP elevation not attributable to another cause. When considering those eyes with a history of glaucoma, eight out of 25 (32 %) in the corticosteroid group had an elevated IOP in the first week or later, whereas there were no eyes out of 17 (0 %) in the Bromday group.Conclusions:Bromfenac is a safe and effective non-steroidal anti-inflammatory drug (NSAID) when used in the post-operative management of cataract surgery. It appears to be as effective as a topical steroid, even when used alone, without the risk of elevated IOP.